ERBB2 and breast neoplasm: Invasive primary or metastatic breast tumors with HER2 gene amplification or protein overexpression can be targeted by trastuzumab therapy, which binds to the extracellular domain and suppresses downstream signaling pathways, leading to improved outcomes [8, 9].